Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Issue 7 (13th May 2017)

• Record Type: Journal Article
• Authors: Whitwell, Jennifer L.; Höglinger, Günter U.; Antonini, Angelo; Bordelon, Yvette; Boxer, Adam L.; Colosimo, Carlo; van Eimeren, Thilo; Golbe, Lawrence I.; Kassubek, Jan; Kurz, Carolin; Litvan, Irene; Pantelyat, Alexander; Rabinovici, Gil; Respondek, Gesine; Rominger, Axel; Rowe, James B.; Stamelou, Maria; Josephs, Keith A.
• Is Part Of: Movement disorders. Volume 32:Issue 7(2017)
• Page Start: 955
• Page End: 971
• Publication Date: 2017-05-13
• Subjects: progressive supranuclear palsy -- diagnosis -- magnetic resonance imaging -- positron emission tomography -- single-photon emission computed tomography; Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.27038
• Languages: English
• ISSNs: 0885-3185

Abstract

ABSTRACT: PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS‐SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five‐level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group‐level findings, level 2 representing biomarkers with demonstrable individual‐level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field. © 2017 International Parkinson and Movement Disorder Society.